Plus, the shipping pause could bring down Gardasil ... could arise from losing the exclusivity license of its other drug, Keytruda. The cancer therapy drug is one of Merck’s hero products ...

Chongqing Zhifei Biological Products, has stocked up more Gardasil than it can sell. As a result, Merck will stop shipping Gardasil to Zhifei at least until the middle of the year.

The London Company Income Equity portfolio returned 12.3% year-to-date vs. a 14.4% increase in the Russell 1000 Value Index.

Factoring the Gardasil shipment pause into the equation ... Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain' Elsewhere, Merck’s ...

Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...

Merck MRK-N said on Tuesday it would not ship its HPV vaccine Gardasil in China ... been one of Merck’s top growth drivers aside from Keytruda, and much of its international growth had come ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at ... papillomavirus (HPV), has been one of Merck's top growth drivers aside from Keytruda, and much of its ...

We recently compiled a list of the Jim Cramer Discusses These 11 Stocks & Finds Few Reasons To Sell. In this article, we are ...